What Is ARKG? ARK Genomic Revolution ETF
Last updated November 2026
Short answer
ARKG is Cathie Wood's actively-managed ARK Invest ETF focused on the genomics and biotech-innovation theme, holding names like Twist Bioscience, 10x Genomics, Tempus AI, CRISPR Therapeutics, and other molecular-diagnostics and gene-editing companies. It is highly concentrated, with around 30 to 35 holdings and the top 10 accounting for roughly two-thirds of assets in October 2026. The fund is very volatile and has suffered a large drawdown since its 2021 peak, with assets falling from about $9 billion to roughly $1.2 billion by early 2026 before recovering to about $2.2 billion by October 2026 as biotech rallied (the price was up 62.1% year to date as of October 16, 2026). It is a high-risk thematic fund built around speculative, often unprofitable biotech companies.
ARKG is issued by ARK Invest and tracks Actively managed (no index); focused on genomics and biotech innovation. It charges a 0.75% expense ratio, holds approximately approximately $2.2 billion in assets under management, yields about 0.00% (does not currently pay a dividend), and launched in October 31, 2014.
What is ARKG?
ARKG is Cathie Wood's actively-managed ARK Invest ETF focused on the genomics and biotech-innovation theme, holding names like Twist Bioscience, 10x Genomics, Tempus AI, CRISPR Therapeutics, and other molecular-diagnostics and gene-editing companies. It is highly concentrated, with around 30 to 35 holdings and the top 10 accounting for roughly two-thirds of assets in October 2026. The fund is very volatile and has suffered a large drawdown since its 2021 peak, with assets falling from about $9 billion to roughly $1.2 billion by early 2026 before recovering to about $2.2 billion by October 2026 as biotech rallied (the price was up 62.1% year to date as of October 16, 2026). It is a high-risk thematic fund built around speculative, often unprofitable biotech companies.
ARKG is issued by ARK Invest and tracks Actively managed (no index); focused on genomics and biotech innovation, so a single ticker gives you the whole portfolio of underlying holdings, weighted by the index's methodology. Nobody is actively picking the stocks.
What does ARKG hold?
ARKG is weighted toward its largest constituents. As of October 2026, the top holdings are:
| Rank | Ticker | Company | % of ARKG | |
|---|---|---|---|---|
| 1 | TWST | Twist Bioscience Corp. | 10.3% | |
| 2 | TXG | 10x Genomics Inc. | 10.0% | |
| 3 | TEM | Tempus AI Inc. | 8.9% | |
| 4 | CRSP | CRISPR Therapeutics AG | 5.2% | |
| 5 | ABSI | Absci Corp. | 5.1% | |
| 6 | PSNL | Personalis Inc. | 4.9% | |
| 7 | GH | Guardant Health Inc. | 4.6% | |
| 8 | NTRA | Natera Inc. | 4.5% | |
| 9 | ILMN | Illumina Inc. | 4.5% | |
| 10 | CDNA | CareDx Inc. | 4.3% |
The remaining holdings make up the balance of the fund, with weights tapering off below the top names. Because the index reconstitutes on a rolling basis, the roster stays current without active management. Each ticker above links to its individual stock guide in Walnut.
How do I invest in ARKG?
There are three common ways to get ARKG exposure. Buy shares (or fractional shares) of ARKG directly at any major broker that lists it. Hold it as a core position and layer more concentrated ideas on top. Or build it into a thematic portfolio in Walnut, so ARKG sits alongside other holdings that express the same thesis, with target weights you can rebalance toward. ARKG trades like a stock during market hours, so you buy it the same way you would any listed share.
New to buying funds? See how to buy an ETF, step by step.
Is ARKG a good buy?
Whether ARKG is a good buy depends less on any single call and more on your time horizon and what you already hold: it tracks Actively managed (no index); focused on genomics and biotech innovation, so what you are deciding is whether you want that exposure in your mix and at what weight. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is ARKG a buy?
The bottom line on ARKG
ARKG offers concentrated, actively-managed exposure to genomics and gene-editing innovation, but it is highly volatile and dominated by speculative, often pre-profit biotech names. It has experienced a severe drawdown since its early-2021 peak, so it suits only investors comfortable with sharp swings and the risk of large, prolonged losses.
More on ARKG
Whether ARKG is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is ARKG a buy?
ARKG yields 0.00% (does not currently pay a dividend) as of October 2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see ARKG dividend: yield and schedule.
For what analysts expect from the companies ARKG holds, its yield as a guide to income, and why no one publishes a price target for the fund itself, see the ARKG forecast.
New to funds like ARKG? Start with what an ETF is, then how to buy an ETF, or browse the full guide to ETF investing.
Wondering how ARKG fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about ARKG
Ask Walnut's AI anything about ARKG and see how it fits what you own.
FAQ
What is ARKG?
+
ARKG is the ARK Genomic Revolution ETF, an actively-managed fund from Cathie Wood's ARK Invest. It invests in companies tied to the genomics revolution, including gene editing, molecular diagnostics, biotechnology, and AI-driven drug discovery, holding names like CRISPR Therapeutics, Tempus AI, and Twist Bioscience.
What is ARKG's expense ratio?
+
ARKG has an expense ratio of 0.75%, which means about $7.50 in annual fees per $1,000 invested. That is high relative to passive index ETFs but typical for an actively-managed thematic fund.
Is ARKG actively managed?
+
Yes. ARKG is actively managed by ARK Invest and does not track an index. The management team selects and weights holdings based on its own research into genomics and biotech innovation, so the portfolio changes over time as ARK's convictions shift.
What does ARKG hold?
+
ARKG holds a concentrated portfolio of roughly 30 to 35 genomics and biotech-innovation stocks. Top holdings as of October 2026 include Twist Bioscience, 10x Genomics, Tempus AI, CRISPR Therapeutics, and Absci, followed by diagnostics names Personalis, Guardant Health, Natera, Illumina, and CareDx, with the top 10 making up around two-thirds of assets. Many holdings are early-stage, pre-profit biotech companies.
Does ARKG pay a dividend?
+
ARKG does not currently pay a meaningful dividend; its yield is effectively 0%. Most of its holdings are growth-oriented, often unprofitable biotech companies that reinvest any cash they generate, so ARKG is not an income-focused fund.
Is ARKG a good investment?
+
Whether ARKG fits a portfolio depends on your goals, risk tolerance, and time horizon. It is a high-risk, very volatile thematic fund that has had a large drawdown since 2021. Walnut is informational, not investment advice, so consider doing your own research or consulting a licensed financial professional.
How volatile is ARKG and how big has its drawdown been?
+
ARKG is extremely volatile because it concentrates in speculative, often pre-profit biotech and gene-editing stocks. Since its early-2021 peak it has fallen dramatically, with assets dropping from roughly $9 billion to about $1.2 billion by early 2026. That was a deep and prolonged drawdown, one that investors should expect could repeat. The swings run both ways: the price then rose 62.1% in 2026 through October 16, yet dropped 8.4% in the single month before that date. Yahoo Finance listed its three-year beta at 2.21.
How concentrated is ARKG?
+
ARKG is highly concentrated for an ETF, holding only about 30 to 35 positions with the top 10 accounting for roughly two-thirds of assets. Single names such as Twist Bioscience and 10x Genomics each represented about 10% of the fund in October 2026, so company-specific news can move ARKG sharply.
What has ARK been buying in ARKG lately?
+
In early October 2026 ARK Invest reported adding to healthcare names including CRISPR Therapeutics, Intellia Therapeutics and Compass Pathways across its funds, while trimming large-cap tech elsewhere. Because ARKG is actively managed, its holdings and weights can shift week to week, so the list on this page is a snapshot from October 2026.
How do I compare ARKG to similar ETFs?
+
Put a few fields side by side: the expense ratio (fees compound over decades), the index or strategy it tracks, the top holdings and how much they overlap with what you already own, the dividend yield, and the AUM, liquidity, and bid-ask spread that affect trading costs. For index funds, tracking error (how closely it follows its index) and tax efficiency matter too. ARKG's figures are above; the full method is in Walnut's guide on how to compare ETFs.
Guides that feature ARKG
ARKG is one of the names covered in these guides. Each one puts the fund next to its peers so you can see where it fits rather than judging it alone.
Related ETFs
Walnut is informational, not investment advice. Holdings weights and fund statistics on this page are approximations stamped to October 2026; verify current figures against ARK Invest's fund page or your broker before investing.